Minneapolis, MN and London, UK – April 25, 2022 – OneMedNet Corporation, the leading curator of regulatory-grade Imaging Real Word Data (“RWD”) and Data Knights Acquisition Corp. (“Data Knights”) (Nasdaq: DKDCA, DKDCW), a special purpose acquisition company, today announced the signing of a definitive business combination agreement that will result in a newly combined company (the “Company”) named OneMedNet to be listed under the symbol ONMD. Upon the closing of the transaction, OneMedNet will continue to be led by its CEO, Mr. Paul Casey, a 40-year public company veteran with a proven track record driving value creation and expansion. The boards of directors of OneMedNet and Data Knights Acquisition Corp. have unanimously approved the transaction.

OneMedNet’s innovation solutions connect healthcare providers and patients, offering direct access to clinical images and associated contextual patient record. OneMedNet proved the commercial and regulatory viability of imaging RWD, a promising emerging market, and provides regulatory-grade image-centric RWD that exactly matches OneMedNet’s Life Science Partners’ Case Selection Protocol. With a growing federated network of 90+ healthcare providers, OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a Federated group of healthcare facilities.

Paul Casey, CEO of OneMedNet, commented, “Today’s announcement is a tremendous milestone for OneMedNet. Since joining the board of OneMedNet in 2021, and most recently assuming the CEO role, my focus has been on readying the Company for its journey as a publicly traded entity. This merger is the next, necessary step in our incredible journey and through this transaction we will be further positioned to fuel our growth trajectory. OneMedNet is uniquely positioned within the clinical trial and clinical research industries, which together represent a $400 billion market. Our runway is limitless and this merger with Data Knights is just the beginning.”
Mr. Jeffrey Yu, Founder and Chairman of OneMedNet added, “With the merger contemplated in today’s announcement, OneMedNet will have the added resources to accelerate and expand our quest to speed diagnostics and therapeutics to market. As evident by the COVID-19 pandemic, diseases and viruses evolve and spread quickly, speed is essential in the industry we serve. By providing regulatory grade RWD meeting FDA and other worldwide regulatory requirements, we enable life sciences companies to bring safer, more effective cures, vaccines, medical devices and artificial intelligence to market faster at a lesser expense.”

Business Affairs Homepage